Loncar Cancer Immunotherapy Etf Beta
| CNCR Etf | USD 14.19 0.37 2.68% |
Loncar Cancer Immunotherapy fundamentals help investors to digest information that contributes to Loncar Cancer's financial success or failures. It also enables traders to predict the movement of Loncar Etf. The fundamental analysis module provides a way to measure Loncar Cancer's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Loncar Cancer etf.
Loncar |
Loncar Cancer Immunotherapy ETF Beta Analysis
Loncar Cancer's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Loncar Cancer Beta | 0.95 |
Most of Loncar Cancer's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Loncar Cancer Immunotherapy is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Loncar Cancer Immunotherapy has a Beta of 0.95. This is much higher than that of the Loncar Investments family and significantly higher than that of the Health category. The beta for all United States etfs is notably lower than that of the firm.
Loncar Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Loncar Cancer's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the etfs which would be a good addition to a portfolio. Peer analysis of Loncar Cancer could also be used in its relative valuation, which is a method of valuing Loncar Cancer by comparing valuation metrics of similar companies.Loncar Cancer is currently under evaluation in beta as compared to similar ETFs.
Fund Asset Allocation for Loncar Cancer
The fund invests 99.87% of asset under management in tradable equity instruments, with the rest of investments concentrated in various types of exotic instruments.Asset allocation divides Loncar Cancer's investment portfolio among different asset categories to balance risk and reward by investing in a diversified mix of instruments that align with the investor's goals, risk tolerance, and time horizon. Mutual funds, which pool money from multiple investors to buy a diversified portfolio of securities, use asset allocation strategies to manage the risk and return of their portfolios.
Mutual funds allocate their assets by investing in a diversified portfolio of securities, such as stocks, bonds, cryptocurrencies and cash. The specific mix of these securities is determined by the fund's investment objective and strategy. For example, a stock mutual fund may invest primarily in equities, while a bond mutual fund may invest mainly in fixed-income securities. The fund's manager, responsible for making investment decisions, will buy and sell securities in the fund's portfolio as market conditions and the fund's objectives change.
Loncar Cancer returns are very sensitive to returns on the market. As the market goes up or down, Loncar Cancer is expected to follow.
Loncar Fundamentals
| Price To Earning | 24.63 X | |||
| Price To Book | 1.99 X | |||
| Price To Sales | 1.24 X | |||
| Number Of Employees | 395 | |||
| Beta | 0.95 | |||
| Total Asset | 20.52 M | |||
| One Year Return | 34.40 % | |||
| Three Year Return | (17.40) % | |||
| Five Year Return | (7.90) % | |||
| Net Asset | 20.52 M | |||
| Last Dividend Paid | 0.35 | |||
| Equity Positions Weight | 99.87 % |
About Loncar Cancer Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Loncar Cancer Immunotherapy's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Loncar Cancer using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Loncar Cancer Immunotherapy based on its fundamental data. In general, a quantitative approach, as applied to this etf, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Loncar Cancer
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Loncar Cancer position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Loncar Cancer will appreciate offsetting losses from the drop in the long position's value.Moving together with Loncar Etf
| 0.64 | XLV | Health Care Select | PairCorr |
| 0.69 | VHT | Vanguard Health Care | PairCorr |
| 0.88 | IBB | iShares Biotechnology ETF | PairCorr |
| 0.83 | XBI | SPDR SP Biotech | PairCorr |
Moving against Loncar Etf
| 0.57 | MEME | Roundhill Investments | PairCorr |
| 0.47 | RSPY | Tuttle Capital Management | PairCorr |
| 0.41 | DSJA | DSJA | PairCorr |
| 0.36 | AXP | American Express Fiscal Year End 24th of January 2025 | PairCorr |
The ability to find closely correlated positions to Loncar Cancer could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Loncar Cancer when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Loncar Cancer - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Loncar Cancer Immunotherapy to buy it.
The correlation of Loncar Cancer is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Loncar Cancer moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Loncar Cancer Immuno moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Loncar Cancer can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Loncar Cancer Piotroski F Score and Loncar Cancer Altman Z Score analysis. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
The market value of Loncar Cancer Immuno is measured differently than its book value, which is the value of Loncar that is recorded on the company's balance sheet. Investors also form their own opinion of Loncar Cancer's value that differs from its market value or its book value, called intrinsic value, which is Loncar Cancer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Loncar Cancer's market value can be influenced by many factors that don't directly affect Loncar Cancer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Loncar Cancer's value and its price as these two are different measures arrived at by different means. Investors typically determine if Loncar Cancer is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Loncar Cancer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.